NOTICE TO THE MARKET
MANAGEMENT CHANGE

BIOTOSCANA INVESTMENTS S.A. ("Company" or "GBT") (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that Diego Sanguinetti will leave the company to join the Argentinean governmental with an official post at AFIP (Administración Federal de Ingresos Públicos) from today onwards.

Production, supply chain and logistics will remain with its respective responsible, as it was before his joining.

The management team thanks Mr. Sanguinetti on his short passage and contribution to the Company.

Montevideo, June 29, 2018
BIOTOSCANA INVESTMENTS S.A.
Claudio Coracini
Legal Representative in Brazil

About GBT Grupo Biotoscana
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT’s strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com.